PRO-169

**PRO-169** is a biosimilar candidate to bevacizumab, developed by **Laboratorios Sophia** as an anti-VEGF-A **monoclonal antibody** specifically formulated for **intravitreal administration** to treat retinal neovascularization diseases. It shares the amino acid sequence with bevacizumab but exhibits glycosylation differences, including higher G1F, G2F, sialic acid, and high mannose content. Preclinical studies in rabbits and rhesus monkeys demonstrated intraocular pharmacokinetics comparable to bevacizumab and ranibizumab, with effective inhibition of choroidal neovascularization, reduced retinal thickness, and fluorescein leakage, alongside a favorable safety profile without significant toxicity.[1][2][5]